GlobeImmune cuts 25% of staff

Roughly six months after raising $17.5 million for Phase III work, Louisville, CO-based GlobeImmune says it has laid of 15 of its 60 employees--or 25 percent.  "Basically we were adjusting the organization for what we are working on," CEO Timothy Rodell tells the Daily Camera. "It was a force of business." 2008 Fierce 15 winner GlobeImmue is developing Tarmogens--targeted molecular immunogens--for diseases like hep C and cancer. The developer has reported promising Phase IIb data...